BEACOPP-14 VS BEACOPP-ESC IN PATIENTS WITH HODGKIN'S LYMPHOMA FROM POOR-PROGNOSIS GROUP: PRELIMINARY RESULTS OF PROSPECTIVE RANDOMIZED MULTYCENTER STUDY

被引：0
|
作者：
Kriachok, I. [1 ]
Titorenko, I. [1 ]
Filonenko, K. [1 ]
Aleksik, E. [1 ]
Novosad, O. [1 ]
Kadnikova, T. [1 ]
Kushchevoy, E. [1 ]
Martinchik, A. [1 ]
Pastushenko, Y. [1 ]
机构：
[1] Natl Canc Inst, Kiev, Ukraine
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1366
引用
收藏
页码：550 / 550
页数：1
相关论文
共 50 条
  • [11] Ten-year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9)
    Diehl, V.
    Franklin, J.
    Pfistner, B.
    Engert, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [12] Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease:: Updated results of the German Hodgkin's Lymphoma Study Group.
    Diehl, V
    Franklin, J
    Sieber, M
    Hasenclever, D
    Wolf, J
    Engert, A
    Hermann, R
    Longin, C
    Koch, P
    Wulf, G
    Hänel, M
    Müller-Hermelink, HK
    Dühmke, E
    Loeffler, M
    BLOOD, 2000, 96 (11) : 576A - +
  • [13] Mortality during treatment of patients with advanced Hodgkin's lymphoma undergoing dose escalated BEACOPP chemotherapy: An analysis of the German Hodgkin study group (GHSG).
    Fuchs, M
    Franklin, J
    Klimm, B
    Josting, A
    Pfistner, B
    Engert, A
    Diehl, V
    BLOOD, 2005, 106 (11) : 749A - 749A
  • [14] ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin lymphoma(HL). Preliminary results of HD2000 GISL trial
    Federico, M.
    Luminari, S.
    Olio, M. Dell'
    Merli, F.
    Brugiatelli, M.
    Stelitano, C.
    Mammi, C.
    Musso, M.
    Baldini, L.
    Marcheselli, L.
    Gobbi P G, P. G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 34 - 34
  • [15] BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin lymphoma study group HD9 randomized trial.
    Diehl, V
    Franklin, J
    Paulus, U
    Engert, A
    Wolf, J
    Hasenclever, D
    Duehmke, E
    Georgii, A
    Mueller-Hermelink, HK
    Loeffler, M
    BLOOD, 2001, 98 (11) : 769A - 769A
  • [16] The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG).
    Mueller, Horst
    Nogova, Lucia
    Eichenauer, Dennis A.
    Halbsguth, Teresa
    Nisters-Backes, Hiltrud
    Schober, Thomas
    Eimermacher, Hartmut
    Borchmann, Peter
    Fuchs, Michael
    Engert, Andreas
    Josting, Andreas
    BLOOD, 2008, 112 (11) : 901 - 901
  • [17] PET-2-guided escalated BEACOPP for patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group
    Eichenauer, D. A.
    Kreissl, S.
    Buehnen, I.
    Goergen, H.
    Hartmann, S.
    Fuchs, M.
    von Tresckow, B.
    Engert, A.
    Borchmann, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 87 - 88
  • [18] A pilot study of combined escalated BEACOPP-ABVD therapy for advanced Hodgkin's lymphoma patients with high IPS score: The Israel cooperative lymphoma group
    Avigdor, A
    Bulvik, S
    Nagler, A
    Ben-Bassat, I
    Polliack, A
    ANNALS OF ONCOLOGY, 2005, 16 : 195 - 195
  • [19] Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12
    Diehl, V
    Brillant, C
    Franklin, J
    Engert, A
    Pfistner, B
    Greil, R
    Herrmann, R
    ANNALS OF ONCOLOGY, 2005, 16 : 51 - 51
  • [20] A pilot study of combined escalated BEACOPP-ABVD therapy for advanced Hodgkin's lymphoma patients with high IPS score: The Israel Cooperative Lymphoma Group.
    Avigdor, A
    Bulvik, S
    Shemtov, N
    Levi, I
    Berkowicz, M
    Ben-Yehuda, D
    Blickstein, D
    Goldschmidt, N
    Gural, A
    Kornberg, A
    Libster, D
    Merkel, D
    Naparstek, E
    Raanani, P
    Roth, B
    Volchek, Y
    Nagler, A
    Ben-Bassat, I
    Polliack, A
    BLOOD, 2004, 104 (11) : 228B - 228B
12345